Xin Lang Cai Jing·2026-02-24 11:51Core Viewpoint - Fosun Pharma's subsidiary, Fuhong Hanlin, has engaged in multiple licensing agreements for the commercialization of the drug Srurolizumab Injection in various regions, indicating a strategic expansion in international markets [1][2]. Group 1: Licensing Agreements - On September 30, 2019, Fuhong Hanlin signed an exclusive licensing agreement with KGBio for Srurolizumab Injection, granting KGBio commercialization rights in Southeast Asia, the Middle East, and North Africa [1]. - On August 25, 2023, Fuhong Hanlin entered into another exclusive licensing agreement with KGBio, further solidifying their partnership in the specified regions [1]. - On December 31, 2024, Fuhong Hanlin signed a licensing agreement with Abbott, allowing Abbott to commercialize the product in Latin America and the Caribbean [1]. Group 2: Amendments and Terminations - On February 24, 2026, Fuhong Hanlin and KGBio signed a revised and partially terminated agreement, which included the termination of the 2023 exclusive licensing agreement and the exclusive commercialization rights in all regions except Indonesia [2]. - On the same day, Fuhong Hanlin amended the 2024 licensing agreement with Abbott, expanding the licensed regions and adding regulatory and sales milestone payments [2].